Hepta, a startup founded by veterans from Illumina and Grail, closed $6.7 million in seed funding to commercialize transformer‑based AI that reads cell‑free DNA epigenetic signals for chronic disease detection. The company presented clinical performance for metabolic dysfunction‑associated steatohepatitis (MASH), claiming an AUC of 0.86 for fibrosis detection and arguing the test could improve triage for upcoming MASH therapeutics. Investors include Felicis and Illumina Ventures; Hepta plans to expand datasets, scale its platform, and pursue regulatory milestones to move from research‑use into clinical deployment.